Welcome to our dedicated page for Biomind Labs news (Ticker: BMNDF), a resource for investors and traders seeking the latest updates and insights on Biomind Labs stock.
Biomind Labs Inc. (BMNDF) generates news centered on clinical research, psychedelic-based CNS drug development, and nanotechnology-enabled pharmaceutical formulations. As a clinical-stage biopharmaceutical and biotech research and development company, Biomind uses its news releases to report progress on its proprietary candidates, regulatory milestones and scientific findings related to psychiatric and neurological conditions.
Recent updates highlight BMND08, a 5-MeO-DMT-based sublingual formulation for depression and anxiety in Alzheimer’s disease and Alzheimer’s-related mood disorders. The company has reported Phase 2 clinical trial results for BMND08, including non-psychedelic dosing regimens, mood improvements and preliminary cognitive findings in early stages of mild to moderate Alzheimer’s-related cognitive impairment. Subsequent news has described the transition of BMND08 into FDA-directed activities using a proprietary nano-formulation drug-delivery platform designed to support commercial-stage clinical trials in neuropsychiatric and neurodegenerative disorders.
Biomind’s news flow also covers its broader pipeline, such as BMND01 DMT inhaled and intramuscular formulations, BMND02 5-MeO-DMT nasal thermosensitive gel, BMND06 targeting obesity through neurological and inflammatory pathways, and BMND07 5-MeO-DMT synthesis for pharmaceutical-grade API. The company reports preclinical toxicology and in vitro data, nano pharmaceutical formulations of DMT and 5-MeO-DMT, and mescaline-related research, along with updates on its intellectual property portfolio and patent applications.
Investors and observers can use the Biomind Labs news page on Stock Titan to follow disclosures about clinical trial stages, IND-related developments, continuous disclosure filings with Canadian regulators, and corporate governance events such as board appointments and shareholder meeting outcomes.
Biomind Labs (OTC:BMNDF) announced a non-brokered private placement to issue up to 28,000,000 units at C$0.09 per unit for gross proceeds of up to C$2,520,000. Each Unit includes one common share and one warrant exercisable at C$0.12 for 24 months. The Offering is expected to close on or about February 6, 2026 and is subject to regulatory approvals and customary closing conditions. Securities will be subject to a statutory hold period of four months and one day. Net proceeds are planned for advancement of clinical development programs, regulatory preparations, and general working capital. Securities will not be registered under the U.S. Securities Act and cannot be offered or sold in the United States absent registration or an applicable exemption.
Biomind Labs (OTC:BMNDF) announced on December 3, 2025 that it is advancing its 5‑MeO‑DMT candidate BMND08 into FDA-directed commercial development using a newly engineered proprietary nano‑formulation.
The company reported a Phase 2 signal described as a 100% response rate in Alzheimer's-related mood disorders, said third‑party patent observations were successfully resolved and that the patent application remains in good standing. Biomind is preparing regulatory and technical material for FDA discussion, including pivotal trial design and possible expedited pathways such as Breakthrough Therapy.
The company also granted 6,200,000 incentive stock options at an exercise price of $0.35 expiring November 3, 2030.
Biomind Labs (OTC:BMNDF) announced that the Ontario Securities Commission revoked its cease trade order issued April 4, 2025, effective November 25, 2025, after the company filed required continuous disclosure documents.
The company filed annual audited financial statements, MD&A, officers' certificates for year ended December 31, 2024, interim financials for March 31, June 30 and September 30, 2025, the annual information form for 2024, and Form 51-102F6; all are available on SEDAR+.
The company noted continuing financial constraints, a going concern uncertainty due to ongoing operating losses and the need for additional financing, and said it will hold an annual general and special meeting before February 25, 2026.
Biomind Labs (OTC:BMNDF) filed multiple amended and interim continuous disclosure documents on SEDAR+ on November 18, 2025, including amended MD&A and officers' certificates for year ended Dec 31, 2024 and interim unaudited financials and MD&A for periods through Sep 30, 2025.
The amended MD&A were prepared after a corrective disclosure request from Ontario Securities Commission staff and include enhanced disclosure on business operations, drug candidate programs, period‑over‑period variance explanations, and added audit committee and corporate governance disclosure for 2024.
The company confirmed it remains subject to a cease trade order issued by the Commission on Apr 4, 2025 for earlier failures to file audited 2024 financials; the newly filed documents are now available on SEDAR+.
The board appointed Scott Ackerman as an independent director and Audit Committee member; he is CEO of Emprise Capital and has two decades of restructuring and audit committee experience.
Biomind Labs responds positively to U.S. government's progressive stance on psychedelic therapies, marked by the nomination of a new Health Secretary supportive of innovative mental health solutions. The company's drug candidate BMND08 showed 100% efficacy in Phase II trials, achieving remission from depression, anxiety, and stress by week 5. The company plans to pursue Breakthrough Therapy Designation with the FDA. Biomind's portfolio includes several drug candidates: Triptax™ (FDA IND clearance), BMND01 (DMT), BMND07 (5-MeO-DMT), BMND02 (nasal), and BMND08 (sublingual formulation).
Biomind Labs Inc. (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI) has announced plans to advance a new Phase II clinical trial for its proprietary compound BMND06, targeting obesity treatment through neurological pathways. Key findings from pre-clinical studies include:
1. BMND06 is physiologically safe with low toxicity and no mutagenic effects.
2. It significantly reduces LPS-induced IL-6 levels in colon cancer cell lines, outperforming dexamethasone by fivefold.
3. The compound shows potential in treating obesity as a neurological condition, addressing the global obesity epidemic affecting 2.3 billion people worldwide.
CEO Alejandro Antalich emphasized BMND06's potential to redefine obesity treatment by targeting neuroinflammation and neural pathways regulating metabolism and energy balance.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Biomind Labs (BMNDF)?
What is the market cap of Biomind Labs (BMNDF)?
